Jan 21 (Reuters) - Avacta Group PLC (AVCT.L) :
* AVACTA ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION CLEARANCE OF THE INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR THE SECOND PRE|CISION® MEDICINE, FAP-EXATECAN (AVA6103)
* AVACTA THERAPEUTICS: PHASE 1 CLINICAL STUDY OF FAP-EXD (AVA6103) IS ANTICIPATED TO BEGIN LATER IN Q1 2026 Source text: Further company coverage: (AVCT.L)

ARKG

SBIO

ACRV

<p>Jan 21 (Reuters) - Avacta Group PLC (AVCT.L) :* AVACTA ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION CLEARANCE OF THE INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR THE SECOND PRE|CISION® MEDICINE, FAP-EXATECAN (AVA6103)* AVACTA THERAPEUTICS: PHASE 1 CLINICAL STUDY OF FAP-EXD (AVA6103) IS ANTICIPATED TO BEGIN LATER IN Q1 2026 Source text: Further company coverage: (AVCT.L)</p>

Reuters

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Acrivon Therapeutics

Avacta Announces US FDA Clearance Of The Investigational New Drug Application For The Second pre|CISION Medicine, FAP-Exatecan